MedTrace Logo

Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma

NCT01983748 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-01-28

No results posted yet for this study

Summary

Patients suffering from uveal melanoma (typed positive for monosomy 3 and without evidence for metastases) will be vaccinated over a period of 2 years with Dendritic Cell loaded with autologous Tumor RNA.

200 patients will be included. The Trial is an open multicenter Phase III Trial.

Conditions

Interventions

BIOLOGICAL

Autologous Dendritic Cells loaded with autologous Tumor RNA

Sponsors & Collaborators

  • University Hospital Lübeck

    collaborator OTHER

  • University Hospital Munich

    collaborator OTHER

  • Universitätsklinikum Hamburg-Eppendorf

    collaborator OTHER

  • University Hospital Homburg/Saar

    collaborator UNKNOWN

  • Universitätsklinikum Köln

    collaborator OTHER

  • University Hospital Tuebingen

    collaborator OTHER

  • University Hospital, Essen

    collaborator OTHER

  • Wuerzburg University Hospital

    collaborator OTHER

  • University Hospital Erlangen

    lead OTHER

Principal Investigators

  • Beatrice Schuler-Thurner, MD · University Hospital Erlangen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-05
Primary Completion
2024-08-31
Completion
2024-12-03

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01983748 on ClinicalTrials.gov